** Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 13.6% to $7.86
** ITOS and partner GSK GSK.L say they have terminated development of their experimental lung cancer therapy after its failure to significantly improve progression-free survival in two mid-stage trials
** ITOS says it has initiated a review of strategic alternatives to conserve cash
** "As most investors have already thrown in the towel on TIGIT, the decision to terminate the partnership is viewed as a relief to preserve resources for its Ph 1-stage pipeline" - J.P.Morgan analyst Brian Cheng
** The discontinued drug belongs to a class of treatments focused on the TIGIT receptor that has fallen out of favor in recent years after a spate of clinical setbacks due to low efficacy
** As of last close, ITOS up 4.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。